Q2 2026 Co-Diagnostics Inc Earnings Call Transcript
Key Points
- Co-Diagnostics Inc (CODX) submitted its dual 510(k) and CLIA waiver application to the FDA for its flu A, B and RSV assay on the Co-Dx PCR platform, a major regulatory milestone.
- The company completed extensive analytical and clinical validation studies, including over 10,000 test runs and a clinical study with more than 1,400 patients across 9 U.S. sites.
- Co-Diagnostics Inc (CODX) is advancing its tuberculosis program in India, targeting CDSCO and WHO ERPD submissions later this year, with costs partially supported by NGO partners.
- The company demonstrated platform versatility by completing a proof-of-concept study for an Ebola assay using direct plasma samples, expanding beyond traditional swab-based testing.
- Co-Diagnostics Inc (CODX) reduced total operating expenses to $6.3 million in Q2 2026 from $8.2 million in the prior year, reflecting disciplined cost management.
- The company is expanding its digital infrastructure and AI-enabled capabilities, aiming to create a connected ecosystem for decentralized testing and population-level health insights.
- Co-Diagnostics Inc (CODX) reported minimal revenue of $166,000 in Q2 2026, with limited current revenue levels and variability in gross margin performance.
- The company's net loss for Q2 2026 was $6.3 million, or $1.46 per share, reflecting continued operating losses.
- Cash and cash equivalents decreased significantly to $3.6 million at the end of Q2 2026 from $11.9 million at the end of 2025, indicating a tight liquidity position.
- Co-Diagnostics Inc (CODX) anticipates continued operating losses in the near term and may need to seek additional capital through equity or debt financings, which could lead to dilution.
- The company's regulatory submissions, including the FDA application and TB-related filings, are subject to review and approval, with no guarantee of clearance or commercialization timelines.
- The Ebola assay development is still in early stages, with no clear timeline for regulatory approval or commercial availability, and the company's strategy is to be 'ready when needed' rather than immediate revenue generation.
Thank you for standing by. At this time, I would like to welcome everyone to the Co-Diagnostics, Inc. second quarter 2026 earnings webcast. (Operator Instructions) I would now like to turn the conference over to Andrew Benson, Head of Investor Relations. The floor is yours.
Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co-Diagnostics, we have Dwight Egan, Chief Executive Officer; and Brian Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results from the second quarter ended June 30, 2026. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analyst Q&A.
Before we begin, we would like to inform listeners that certain statements made by Co-Diagnostics during this call, which are not historical facts, are forward-looking statements. In addition to diagnostic test developments and clinical evaluation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
